scholarly journals Prognosis in Patients with Non-Small Cell Lung Cancer Who Received Erlotinib Treatment and Subsequent Dose Reduction due to Skin Rash

Onkologie ◽  
2012 ◽  
Vol 35 (12) ◽  
pp. 747-752 ◽  
Author(s):  
Naoki Takashima ◽  
Tomoki Kimura ◽  
Naohiro Watanabe ◽  
Takumi Umemura ◽  
Shinya Katsuno ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Dose Reduction ◽  
Skin Rash ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Subsequent Dose

scholarly journals Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report

2016 ◽  
Vol 9 (1) ◽  
pp. 51-55 ◽  
Author(s):  
Jun Osugi ◽  
Yuki Owada ◽  
Takumi Yamaura ◽  
Satoshi Muto ◽  
Naoyuki Okabe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Dose Reduction ◽  
Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Small Cell ◽  
Severe Neutropenia ◽  
Small Cell Lung ◽  
Successful Management ◽  
Anaplastic Lymphoma

Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib might be necessary for some patients with severe neutropenia. However, information concerning clinical experience and management of severe neutropenia is currently limited. In this report, the successful management of crizotinib-induced neutropenia by dose reduction of crizotinib in a patient with ALK-positive non-small cell lung cancer is described.

Lung dose reduction in patients with stage III non-small-cell lung cancer using software that estimates patient-specific dose reduction feasibility

2021 ◽  
Vol 85 ◽  
pp. 57-62
Author(s):  
Hidetoshi Shimizu ◽  
Koji Sasaki ◽  
Takahiro Aoyama ◽  
Tohru Iwata ◽  
Tomoki Kitagawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Dose Reduction ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Iii ◽  
Patient Specific ◽  
Lung Dose ◽  
Small Cell Lung

NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients

2018 ◽  
Vol 56 (11) ◽  
pp. 551-554 ◽  
Author(s):  
Yohei Iimura ◽  
Hitoshi Shimomura ◽  
Takeo Yasu ◽  
Keiko Imanaka ◽  
Ryuichi Ogawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Skin Rash ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Egfr Tki
Sign in / Sign up

Export Citation Format

Share Document